Molecular subtypes of breast cancer and cyclooxygenase-2 overexpression: Predictive role in patients treated with adjuvant anthracycline-based chemotherapy
Marcella Mottolese, Pier Giorgio Natali(Unknown), Raffaele Perrone-Donnorso, Letizia Perracchio, Irene Venturo, Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Isabella Sperduti(San Gallicano Hospital), Simonetta Buglioni, Paola Papaldo(Cancer Institute (WIA)), Elisa Melucci
Cancer Research
May 1, 2008
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226